Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated April 27, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing specifically details transactions executed under a programme initiated on February 4, 2026.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance metrics such as revenue or profit.
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period starting February 4, 2026.
- Specific Sub-Programme (Feb 4 - May 4, 2026): Up to DKK 3.8 billion.
- Accumulated Repurchases (as of April 24, 2026): 13,407,992 B shares.
- Total Transaction Value (as of April 24, 2026): DKK 3,438,931,195.
- Average Purchase Price: DKK 256.48 per B share.
- Treasury Shares Held: 30,797,791 B shares (0.7% of total share capital).
- Total Share Capital: 4,465,000,000 shares (including treasury shares).
Material Changes
Since the previous announcement on April 20, 2026, the company executed five additional transactions between April 21 and April 24, 2026. These transactions involved the purchase of 230,000 shares per day, increasing the total accumulated repurchase value from approximately DKK 3.15 billion to DKK 3.44 billion.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 15 billion during the 12-month period beginning February 4, 2026. The company operates under the "Safe Harbour Rules" of the EU Market Abuse Regulation.
Risks and Contingencies: The filing does not disclose specific operational risks or contingencies beyond the standard regulatory framework governing the repurchase programme.
Investor Verification Checklist
- Verify the total remaining capacity under the DKK 15 billion programme (approx. DKK 11.56 billion remaining as of April 24, 2026).
- Confirm the current market price of B shares relative to the average repurchase price of DKK 256.48.
- Review the full transaction history on novonordisk.com for daily execution details.
- Monitor the timeline for the sub-programme ending May 4, 2026, to assess if the DKK 3.8 billion target will be met.